Nemaura Medical Inc (NASDAQ:NMRD) announced Tuesday it is planning to initiate a user study comparing its sugarBEAT continuous glucose monitor (CGM) directly against a highly successful major incumbent CGM sensor.
The company said its goal with the study is to position sugarBEAT as a non-invasive, daily/flexible, cost-effective alternative to traditional, expensive invasive CGMs.
“Our decision to go head-to-head vs a hugely successful CGM sensor was based on positive feedback we received from recent meetings with public health insurers in key territories in Europe,” said CEO Dr Faz Chowdhury in a statement.
“We believe that most people with diabetes do not currently use any continuous glucose monitoring system due to the high costs and the invasiveness of current products. We believe that sugarBEAT changes this paradigm and is the first non-invasive CGM to provide the [masses] an option for daily monitoring whenever they choose at an affordable price point. We believe that this level of flexibility is a better option than any alternative CGM devices with either 7-day, 10-day, or 14-day sensor wear time currently available.”
Chowdhury added: “We believe that sugarBEAT’s flexibility empowers users with very powerful trend data at a lower cost compared to current CGM’s, which we believe will encourage broad adoption of the system.”
SugarBEAT consists of a daily disposable adhesive skin-patch connected to a rechargeable transmitter, with an app displaying glucose readings every five minutes for up to 24 hours. The genius of SugarBEAT lies in its skin-patch technology which allows for better glucose management.
Several studies are planned over the course of this year designed to demonstrate the effectiveness of sugarBEAT to increase Time-In-Range, thus reducing HbA1C with intermittent (non-consecutive days) use over a few days per week or even month.
Initial results from studies comparing the various market-leading CGM devices indicates sugarBEAT’s accuracy to be on par with the major incumbent invasive CGM sensors, using single finger-stick blood glucose meter calibration in real-life settings, the company said.
The first phase of the commercial launch of sugarBEAT began in the UK after Nemaura received CE Mark approval in 2019. In this initial phase, devices were supplied to a limited cohort of users while the company sought to ramp up its manufacturing operations.
The UK licensee of sugarBEAT, DB Ethitronix, is currently finalizing the launch of online sales of sugarBEAT. Concurrently, Nemaura is finalizing the launch of its subscription-based service, BEATdiabetes, aimed at reversing Type 2 diabetes and preventing prediabetes from the onset of diabetes.
The company’s stock recently traded up 16% to $3.79 a share in New York.
Contact the author: [email protected]
Follow him on Twitter @PatrickMGraham